$1.66
-0.21 (-11.05%)
Open$1.87
Previous Close$1.87
Day High$1.87
Day Low$1.65
52W High$4.94
52W Low$1.58
Volume—
Avg Volume37.3K
Market Cap4.53M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,100.6% upside
Current
$1.66
$1.66
Target
$36.53
$36.53
$23.38
$36.53 avg
$47.42
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 4.23M | 3.52M | 899.1K |
| Net Income | -3,812,462 | -2,852,453 | -268,437 |
| Profit Margin | -90.1% | -85.6% | -29.9% |
| EBITDA | -4,031,216 | -3,183,685 | -429,552 |
| Free Cash Flow | — | — | -251,567 |
| Rev Growth | +20.3% | +20.3% | -1.1% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |